- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024
Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, highlighting its safety profile and 100% minimal residual disease (MRD) negativity after cycle 3, and explores how using bispecific antibodies like teclistamab earlier in treatment could influence future options for relapsed/refractory multiple myeloma.
Video content above is prompted by the following:
- Bispecific antibodies have had a significant impact on the treatment landscape for R/R multiple myeloma. Data presented at ASH is evaluating the use of bispecifics earlier in treatment. Briefly describe the data presented on MajesTEC-5, which evaluates teclistamab in combination with standard therapy in the frontline setting.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Primary end point: safety
- Secondary end point: MRD negativity, 100% after cycle 3
- How might using teclistamab in earlier lines of therapy influence treatment options in the relapsed setting?
ICYMI: Highlights From AMCP Nexus 2024
December 26th 2024Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.
Read More
